Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer.

"Declarations Ethics approval and consent to participatePatient was consented to donate clinical samples for this study. This study was approved by the Ethics Committee of The First Affiliated Hospital, Sun Yat-sen University ([2017]043). The use of clinical samples for organoid studies was approved by the Ethics Committee of The Seventh Affiliated Hospital of Sun Yat-sen University (KY-2022-039-02). Consent for publicationInformed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patient(s) to publish this paper. Competing interestsThe authors declare no conflict of interest. Competing interests The authors declare no conflict of interest."

"Funding This study was supported by Natural Science Foundation of Guangdong Province (2018A030313543), China Digestive Cancer Clinical Research Public Welfare Project (P014-107), Guangdong Provincial Key Laboratory of Digestive Cancer Research (2021B1212040006) and Shenzhen Fundamental Research Program (JCYJ20200109142605909 and JCYJ20220818102011022)."